US EditionInnovent to Present Promising Phase 2 Data for Breakthrough Eye Drug IBI302 at ARVO 2025
- Innovent Biologics shared one-year Phase 2 findings on the high-dose IBI302 treatment in Chinese individuals affected by neovascular AMD during the ARVO 2025 meeting held in Salt Lake City.
- The study randomized 132 subjects to three groups, comparing IBI302 doses with aflibercept after assessing disease activity at Week 20 for tailored dosing intervals.
- The trial met its primary endpoint showing IBI302 achieved about +10.5 ETDRS letters BCVA improvement at Week 40, comparable and sustained through Week 52 with over 80% on 12-week dosing.
- Pooled data indicated IBI302 reduced macular atrophy incidence at Week 52 by nearly 40% versus aflibercept, with central subfield thickness reductions favoring IBI302 treatment.
- These promising results establish a basis for further development of IBI302 as a potentially effective extended-interval treatment for nAMD, according to study principal investigator Prof. Xiaodong Sun.
61 Articles
61 Articles
ABC FOX Montana
Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Edema
SAN FRANCISCO and SUZHOU, China, May 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other…
Optigo Biotherapeutics Wins People's Choice Award at Eyecelerator and Presents Compelling Preclinical Data on Long-Acting Intravitreal Biologics at the ARVO 2025 Conference
Optigo wins People's Choice Award at the recent Eyecelerator meeting in Park City for proprietary drug anchoring, potential to transform intravitreal drug delivery Preclinical data demonstrates sustained efficacy and safety for six months or more following a single injection VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Optigo Biotherapeutics, a biotechnology company pioneering long-acting, bi-functional intravitreal biologics, t…
Aspen Daily News
Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025
SAN FRANCISCO and SUZHOU, China, May 5, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announces…
Coverage Details
Bias Distribution
- 82% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
